Texas is currently home to 4873 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Use of Airpod Pros as Assistive Technology
Recruiting
The goal of this study is to investigate the suitability and effectiveness of the AirPod Pro 2nd generation (AP2) as hearing assistive technology for individuals with mild-to-moderate hearing loss when listening in noisy environments. Researchers will compare four types of assistive technology: hearing aids (HAs), AP2, dedicated wireless remote microphones, and Smartphone wireless remote microphone. The main questions it aims to answer are: * Which assistive technology provides the greatest be... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/05/2025
Locations: Callier Center for Communication Disorders, Richardson, Texas
Conditions: Hearing Loss, Adult-Onset, Hearing Aids
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Participants With Immune-Mediated Diseases (Ntrust-2)
Recruiting
This is an open-label, multi-center, multi-cohort, non-randomized Phase 1 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with Immune-Mediated Diseases (IMD) including systemic sclerosis \[SSc\], idiopathic inflammatory myopathies \[IIM\], and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis \[AAV\].
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2025
Locations: Nkarta Investigational Site, Dallas, Texas
Conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
Recruiting
The purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2025
Locations: Research Site, Sherman, Texas
Conditions: Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Recruiting
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Texas Oncology Dfw, Dallas, Texas
Conditions: Chronic Lymphocytic Leukemia
A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with RO7790121 compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
06/05/2025
Locations: Amel Med LLC, Georgetown, Texas
Conditions: Moderately to Severely Active Ulcerative Colitis
The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)
Recruiting
This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk MDS, or more recently defined as myelodysplastic neoplasms, with or without ring sideroblasts. The study is divided into the Screening Period, Double-blind Treatment Period, Safety Follow-Up Period and Long-term Follow-up Period. Approximately 255 participants will be enrolled, randomized 2:1 to re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Study Site 1106, Houston, Texas
Conditions: Myelodysplastic Syndromes
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
Recruiting
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
06/05/2025
Locations: KalVista Investigative Site, Dallas, Texas
Conditions: Hereditary Angioedema
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
Recruiting
This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, PALB2 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Recruiting
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/05/2025
Locations: Retina Research Institute of Texas, Abilene, Texas
Conditions: Age Related Macular Degeneration (ARMD)
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin a... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/05/2025
Locations: Research Site, Arlington, Texas
Conditions: Chronic Kidney Disease and Hypertension
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
Recruiting
This study investigates whether alteplase can help to improve pleural fluid drainage and dyspnea (breathlessness) in patients with non-draining malignant pleural effusion. Alteplase helps dissolve blood clots and is used to treat heart attacks, strokes, and clots in the lungs. Alteplase may help to control symptoms of breathlessness.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Study of AZD9829 in CD123+ Hematological Malignancies
Recruiting
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Research Site, Houston, Texas
Conditions: Hematological Malignancies